- Manage disclosure of pivotal Phase 3 data
- Define clinical success in atopic dermatitis (AD)
- Differentiate topical treatment from available and investigational therapies
How do you help an emerging biotech disclose highly anticipated Phase 3 results and demonstrate the value this therapy can potentially bring to patients?
“If approved crisaborole could become a significant first-in-class treatment option for patients with mild-to-moderate atopic dermatitis.” – Amy Paller, MD, Northwestern University